These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38719068)

  • 1. A workflow to practically apply true dose considerations to in vitro testing for next generation risk assessment.
    Nicol B; Vandenbossche-Goddard E; Thorpe C; Newman R; Patel H; Yates D
    Toxicology; 2024 Jun; 505():153826. PubMed ID: 38719068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Next generation risk assessment for occupational chemical safety - A real world example with sodium-2-hydroxyethane sulfonate.
    Wood A; Breffa C; Chaine C; Cubberley R; Dent M; Eichhorn J; Fayyaz S; Grimm FA; Houghton J; Kiwamoto R; Kukic P; Lee M; Malcomber S; Martin S; Nicol B; Reynolds J; Riley G; Scott S; Smith C; Westmoreland C; Wieland W; Williams M; Wolton K; Zellmann T; Gutsell S
    Toxicology; 2024 Aug; 506():153835. PubMed ID: 38857863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a next generation risk assessment framework for the evaluation of skin sensitisation of cosmetic ingredients.
    Gilmour N; Kern PS; Alépée N; Boislève F; Bury D; Clouet E; Hirota M; Hoffmann S; Kühnl J; Lalko JF; Mewes K; Miyazawa M; Nishida H; Osmani A; Petersohn D; Sekine S; van Vliet E; Klaric M
    Regul Toxicol Pharmacol; 2020 Oct; 116():104721. PubMed ID: 32645429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose metric considerations in in vitro assays to improve quantitative in vitro-in vivo dose extrapolations.
    Groothuis FA; Heringa MB; Nicol B; Hermens JL; Blaauboer BJ; Kramer NI
    Toxicology; 2015 Jun; 332():30-40. PubMed ID: 23978460
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment.
    Adeleye Y; Andersen M; Clewell R; Davies M; Dent M; Edwards S; Fowler P; Malcomber S; Nicol B; Scott A; Scott S; Sun B; Westmoreland C; White A; Zhang Q; Carmichael PL
    Toxicology; 2015 Jun; 332():102-11. PubMed ID: 24582757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards grouping concepts based on new approach methodologies in chemical hazard assessment: the read-across approach of the EU-ToxRisk project.
    Escher SE; Kamp H; Bennekou SH; Bitsch A; Fisher C; Graepel R; Hengstler JG; Herzler M; Knight D; Leist M; Norinder U; Ouédraogo G; Pastor M; Stuard S; White A; Zdrazil B; van de Water B; Kroese D
    Arch Toxicol; 2019 Dec; 93(12):3643-3667. PubMed ID: 31781791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Next generation risk assessment: an
    Ebmeyer J; Najjar A; Lange D; Boettcher M; Voß S; Brandmair K; Meinhardt J; Kuehnl J; Hewitt NJ; Krueger CT; Schepky A
    Front Pharmacol; 2024; 15():1345992. PubMed ID: 38515841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.
    Li H; Yuan H; Middleton A; Li J; Nicol B; Carmichael P; Guo J; Peng S; Zhang Q
    Toxicol In Vitro; 2021 Aug; 74():105171. PubMed ID: 33848589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A 10-step framework for use of read-across (RAX) in next generation risk assessment (NGRA) for cosmetics safety assessment.
    Alexander-White C; Bury D; Cronin M; Dent M; Hack E; Hewitt NJ; Kenna G; Naciff J; Ouedraogo G; Schepky A; Mahony C; Europe C
    Regul Toxicol Pharmacol; 2022 Mar; 129():105094. PubMed ID: 34990780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next Generation Risk Assessment of the Anti-Androgen Flutamide Including the Contribution of Its Active Metabolite Hydroxyflutamide.
    van Tongeren TCA; Carmichael PL; Rietjens IMCM; Li H
    Front Toxicol; 2022; 4():881235. PubMed ID: 35722059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ab initio chemical safety assessment: A workflow based on exposure considerations and non-animal methods.
    Berggren E; White A; Ouedraogo G; Paini A; Richarz AN; Bois FY; Exner T; Leite S; Grunsven LAV; Worth A; Mahony C
    Comput Toxicol; 2017 Nov; 4():31-44. PubMed ID: 29214231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COSMOS next generation - A public knowledge base leveraging chemical and biological data to support the regulatory assessment of chemicals.
    Yang C; Cronin MTD; Arvidson KB; Bienfait B; Enoch SJ; Heldreth B; Hobocienski B; Muldoon-Jacobs K; Lan Y; Madden JC; Magdziarz T; Marusczyk J; Mostrag A; Nelms M; Neagu D; Przybylak K; Rathman JF; Park J; Richarz AN; Richard AM; Ribeiro JV; Sacher O; Schwab C; Vitcheva V; Volarath P; Worth AP
    Comput Toxicol; 2021 Aug; 19():100175. PubMed ID: 34405124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of fit-for-purpose assays within tiered testing approaches: A case study evaluating prioritized estrogen-active compounds in an in vitro human uterotrophic assay.
    Beames T; Moreau M; Roberts LA; Mansouri K; Haider S; Smeltz M; Nicolas CI; Doheny D; Phillips MB; Yoon M; Becker RA; McMullen PD; Andersen ME; Clewell RA; Hartman JK
    Toxicol Appl Pharmacol; 2020 Jan; 387():114774. PubMed ID: 31783037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. From vision toward best practices: Evaluating
    Reardon AJF; Farmahin R; Williams A; Meier MJ; Addicks GC; Yauk CL; Matteo G; Atlas E; Harrill J; Everett LJ; Shah I; Judson R; Ramaiahgari S; Ferguson SS; Barton-Maclaren TS
    Front Toxicol; 2023; 5():1194895. PubMed ID: 37288009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Next generation risk assessment for skin allergy: Decision making using new approach methodologies.
    Gilmour N; Reynolds J; Przybylak K; Aleksic M; Aptula N; Baltazar MT; Cubberley R; Rajagopal R; Reynolds G; Spriggs S; Thorpe C; Windebank S; Maxwell G
    Regul Toxicol Pharmacol; 2022 Jun; 131():105159. PubMed ID: 35311660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applying a next generation risk assessment framework for skin sensitisation to inconsistent new approach methodology information.
    Gilmour N; Alépée N; Hoffmann S; Kern PS; Van Vliet E; Bury D; Miyazawa M; Nishida H; Cosmetics Europe
    ALTEX; 2023; 40(3):439-451. PubMed ID: 36919358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation risk assessment for skin sensitisation: A case study with propyl paraben.
    Assaf Vandecasteele H; Gautier F; Tourneix F; Vliet EV; Bury D; Alépée N
    Regul Toxicol Pharmacol; 2021 Jul; 123():104936. PubMed ID: 33905779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next generation testing strategy for assessment of genomic damage: A conceptual framework and considerations.
    Dearfield KL; Gollapudi BB; Bemis JC; Benz RD; Douglas GR; Elespuru RK; Johnson GE; Kirkland DJ; LeBaron MJ; Li AP; Marchetti F; Pottenger LH; Rorije E; Tanir JY; Thybaud V; van Benthem J; Yauk CL; Zeiger E; Luijten M
    Environ Mol Mutagen; 2017 Jun; 58(5):264-283. PubMed ID: 27650663
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrating in vitro testing and physiologically-based pharmacokinetic (PBPK) modelling for chemical liver toxicity assessment-A case study of troglitazone.
    Yu L; Li H; Zhang C; Zhang Q; Guo J; Li J; Yuan H; Li L; Carmichael P; Peng S
    Environ Toxicol Pharmacol; 2020 Feb; 74():103296. PubMed ID: 31783317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.